Koers Biovica International AB (publ) Nasdaq Stockholm
Aandelen
SE0008613731
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 10 mln. 925K 859K | Omzet 2025 * | 116 mln. 10,73 mln. 9,96 mln. | Marktkapitalisatie | 135 mln. 12,51 mln. 11,62 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -115 mln. -10,63 mln. -9,88 mln. | Nettowinst (verlies) 2025 * | -60 mln. -5,55 mln. -5,15 mln. | EV/omzet 2024 * | 6,18 x |
Nettoliquiditeiten 2024 * | 73,52 mln. 6,8 mln. 6,32 mln. | Nettoliquiditeiten 2025 * | 45,95 mln. 4,25 mln. 3,95 mln. | EV/omzet 2025 * | 0,77 x |
K/w-verhouding 2024 * |
-0,22
x | K/w-verhouding 2025 * |
-0,56
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,54% |
Recentste transcriptie over Biovica International AB (publ)
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Anders Rylander
CEO | Chief Executive Officer | 54 | 01-01-10 |
Anders Morén
DFI | Director of Finance/CFO | 59 | 01-01-23 |
Hanna Ritzen
CTO | Chief Tech/Sci/R&D Officer | 45 | 01-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 64 | 20-03-19 | |
Annika Berg
BRD | Director/Board Member | 61 | 01-01-20 |
Maria Holmlund
BRD | Director/Board Member | 68 | 01-01-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-16,10% | 11,41 mld. | |
-30,20% | 2,3 mld. | |
-14,31% | 2,16 mld. | |
-26,03% | 1,56 mld. | |
+36,95% | 1,19 mld. | |
-2,40% | 760 mln. | |
-19,00% | 506 mln. | |
-38,57% | 444 mln. | |
+13,72% | 339 mln. |